罗欣药业(002793) - 2024 Q2 - 季度业绩预告

Financial Performance - The estimated net profit for the first half of 2024 is projected to be a loss of between 60 million RMB and 120 million RMB, compared to a loss of 126.89 million RMB in the same period last year[2]. - The estimated net profit after deducting non-recurring gains and losses is projected to be a loss of between 85 million RMB and 145 million RMB, compared to a loss of 147.08 million RMB in the same period last year[2]. - The basic earnings per share is estimated to be a loss of between 0.06 RMB and 0.11 RMB per share, compared to a loss of 0.12 RMB per share in the same period last year[2]. - The financial data in the performance forecast is a preliminary estimate and has not been audited by accountants[9]. - The company emphasizes the importance of cautious decision-making for investors and highlights the associated investment risks[9]. Innovative Drug Development - The company has made significant progress in the market introduction of its innovative drug Tegolarsen tablets, with sales showing a notable increase compared to the same period last year[8]. - The innovative drug business has not yet covered its costs, resulting in continued losses for the company[8]. - The company is actively enhancing market development and deepening cooperation with medical institutions to improve product accessibility and recognition[8]. - The company is also advancing research and development of other innovative drugs to enrich its product pipeline and increase core competitiveness[8]. Performance Forecast Period - The performance forecast period is from January 1, 2024, to June 30, 2024[7].